S Arnolds

Summary

Affiliation: Profil Institute for Metabolic Research
Country: Germany

Publications

  1. pmc Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study
    Sabine Arnolds
    Profil Institut für Stoffwechselforschung, Neuss, Germany
    Diabetes Care 33:1509-15. 2010
  2. pmc How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes
    S Arnolds
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    Int J Clin Pract 64:1415-24. 2010
  3. doi request reprint Insulin aspart has a shorter duration of action than human insulin over a wide dose-range
    L Nosek
    Profil Institute for Metabolic Research, Neuss, Germany
    Diabetes Obes Metab 15:77-83. 2013
  4. doi request reprint Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers
    S Arnolds
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany lresearch de
    Exp Clin Endocrinol Diabetes 118:662-4. 2010
  5. doi request reprint Spectrum of Diabetes Research does not Reflect Patients' Scientific Preferences: A Longitudinal Evaluation of Diabetes Research Areas 2010-2013 vs. a Cross-sectional Survey in Patients with Diabetes
    S Arnolds
    Profil, Neuss, Germany
    Exp Clin Endocrinol Diabetes 123:299-302. 2015

Collaborators

Detail Information

Publications5

  1. pmc Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study
    Sabine Arnolds
    Profil Institut für Stoffwechselforschung, Neuss, Germany
    Diabetes Care 33:1509-15. 2010
    ..i.d.) or sitagliptin (SITA) (100 mg once daily) in response to a standardized breakfast meal challenge in 48 men or women with type 2 diabetes receiving insulin glargine (GLAR) + metformin (MET)...
  2. pmc How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes
    S Arnolds
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
    Int J Clin Pract 64:1415-24. 2010
    ..Finally, the necessity of overcoming patient and/or physician barriers to insulin therapy and providing continuing education and training is emphasised...
  3. doi request reprint Insulin aspart has a shorter duration of action than human insulin over a wide dose-range
    L Nosek
    Profil Institute for Metabolic Research, Neuss, Germany
    Diabetes Obes Metab 15:77-83. 2013
    ..This study compared late metabolic activity (4-12 and 6-12 h post-dosing) and duration of action (time to reach late half-maximal activity) over a range of doses between insulin aspart (IAsp) and RHI...
  4. doi request reprint Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers
    S Arnolds
    Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany lresearch de
    Exp Clin Endocrinol Diabetes 118:662-4. 2010
    ..Because of its zinc-free formulation insulin glulisine (GLU) might have a faster onset of action than other short-acting analogues. We compared the pharmacokinetics and pharmacodynamics of GLU with those of insulin aspart (ASP)...
  5. doi request reprint Spectrum of Diabetes Research does not Reflect Patients' Scientific Preferences: A Longitudinal Evaluation of Diabetes Research Areas 2010-2013 vs. a Cross-sectional Survey in Patients with Diabetes
    S Arnolds
    Profil, Neuss, Germany
    Exp Clin Endocrinol Diabetes 123:299-302. 2015
    ..To compare the proportions and trends in the distribution of research topics as presented during the annual meetings 2010-2013 of the European Association for the Study of Diabetes (EASD) to patients' preferences...